Inside Health Policy quotes Scott (again)

In its article on Lilly's introduction of DTC discounted vials of Zepbound, IHP included a great quote from CEO Scott Brunner:

“It’s a much more rational and care-focused response to the remarkable demand for their drug than the lawsuits and cease-and-desist letters Lilly has been raining down on compounding pharmacies,” he said. “For 20 months now, compounders have been a lifeline for many patients, filling prescriptions for compounded tirzepatide injection at a time when the FDA-approved drug has been in shortage."